← Pfizer overview

Pfizer vs Amgen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Pfizer Inc (PFE)

Q3 2026
▲3▼1

Pfizer gains on pricing deal, raised guidance, pipeline progress

  • Voluntary drug-pricing deal cuts regulatory risk Pfizer struck a voluntary deal on drug pricing, reducing the threat of new regulations. This lowers uncertainty and helps the company plan without fear of sudden price controls.

    It was a major positive event that reduced regulatory overhang and boosted investor confidence.

  • Q2 earnings beat and 2026 guidance raised Pfizer reported better-than-expected second-quarter results and raised its full-year 2026 revenue forecast to $60.5–$62.5 billion. This signals stronger business performance than previously thought.

    Earnings beats and raised guidance are key drivers of stock price and show improving fundamentals.

  • Cost cuts expanded, pipeline reaches 95 programs Pfizer increased its cost-cutting target to $2.5 billion and now has 95 pipeline programs. Label expansions and new bets in obesity, oncology, Lyme, eczema, and vitiligo aim to boost future revenue.

    Cost savings and pipeline growth are positive for future earnings and show management action.

  • Patent expirations, competition, and debt weigh on outlook Upcoming patent expirations for Ibrance and Eliquis, pricing pressure, Moderna’s new approvals, $60.5 billion debt, and a thinly covered dividend pose risks. Growth was only 1% with a net loss.

    These are significant headwinds that could limit upside and pressure the stock.

September 2026
▲2▼2

Pfizer advances pipeline but faces competition, legal, and financial risks

  • Pipeline and new product momentum Pfizer is advancing growth bets in oncology, obesity, and new drugs like eczema treatment tilrekimig and vitiligo therapy LITFULO. Pipeline programs reached 95, and international new-product sales climbed to $4 billion, showing progress in diversifying beyond COVID.

    This highlights the key positive development that could drive future revenue growth.

  • Cost cuts and productivity gains Cost cuts and tripled sales-force productivity help offset shrinking COVID revenue. This efficiency improvement supports profitability despite top-line pressures.

    This shows management's efforts to improve financial health, a positive factor for the stock.

  • Intensifying competition and guidance concerns Moderna's new COVID and mRNA flu approvals intensify competition, while 2026 guidance sits below 2025 amid patent expirations. This creates uncertainty about Pfizer's ability to grow revenue.

    This is a major negative factor weighing on investor sentiment and future earnings.

  • Financial and legal risks The 6.19% dividend is thinly covered by free cash flow alongside $60.5 billion in debt. Overseas revenue-sharing under the most-favored-nation deal caps pricing upside through 2029, and Monsanto's mRNA patent lawsuit survived dismissal, creating legal and financial uncertainty.

    These factors pose significant risks to Pfizer's financial stability and stock performance.

Latest
▲2▼2

Pfizer's pipeline wins offset pricing and patent setbacks

  • Overseas revenue sharing caps pricing upside Pfizer must share part of any extra overseas drug revenue with the U.S. government under its most-favored-nation pricing deal, running through early 2029. This limits how much Pfizer can profit from higher prices abroad, a direct hit to future earnings and a drag on the stock.

    New pricing rule directly reduces Pfizer's overseas profit potential.

  • New products and cost cuts offset COVID decline Pfizer said new and acquired medicines, vaccines and oncology products grew from $500 million in 2023 to $4 billion internationally, with $3.2 billion in Q2 alone. It also cut costs and tripled sales-force productivity, showing the growth story is delivering as COVID revenue shrinks.

    Shows the core strategy replacing lost COVID revenue is working.

  • Pipeline wins in eczema and vitiligo Pfizer's eczema drug tilrekimig met its Phase 2 goal with strong skin clearance, and LITFULO hit Phase 3 targets in vitiligo, with regulatory filings planned. These are new growth candidates beyond COVID, supporting the long-term pipeline story investors are counting on.

    Two positive trial results add fresh pipeline value beyond existing drugs.

  • Monsanto mRNA patent lawsuit moves forward A Delaware judge rejected Pfizer's bid to dismiss Monsanto's mRNA patent infringement lawsuit over its COVID-19 vaccines. The case now proceeds, creating legal uncertainty and potential financial liability that could weigh on the stock until resolved.

    New legal setback adds uncertainty and potential cost for Pfizer.

▲2▼2

Pfizer's growth bets advance as cash and patent worries weigh

  • Moderna's new approvals add COVID and flu competition Moderna won FDA approval for updated COVID shots and the first mRNA flu vaccine for older adults. That means more rivals fighting for the same pharmacy shelf space and patient visits, which can pressure Pfizer's COVID vaccine sales and slow its push into flu.

    New competitive threat directly affecting Pfizer's respiratory vaccine revenue.

  • Oncology sales and pipeline strengthen Pfizer's cancer business grew 3% to $4.17 billion last quarter, led by Padcev, up 23%, after an FDA approval expanded its patient pool. Pfizer is also testing a promising new cancer drug and aims for eight or more blockbuster cancer medicines by 2030, giving investors a concrete growth engine.

    Shows a real, current revenue driver offsetting declines elsewhere.

  • Obesity and oncology pipeline is the growth story Pfizer now has 95 pipeline programs, with the biggest bets in obesity and cancer. Its monthly obesity shot berobenatide could launch around 2028 in a market expected to reach $114 billion. Progress here is what investors are counting on to replace lost COVID and patent revenue.

    Explains the long-term growth thesis that supports the stock.

  • Dividend and 2026 guidance under pressure Pfizer's 6.19% dividend is only thinly covered by free cash flow, with $60.5 billion of debt competing for the same cash. Management also guided 2026 revenue and earnings below 2025 levels as COVID sales collapse and patents expire. That combination limits financial flexibility and keeps a lid on the stock.

    Highlights the main financial risk weighing on Pfizer's valuation.

August 2026
▲3▼1

Pfizer raises guidance, cuts costs, advances pipeline despite patent and pricing risks

  • Guidance raised on non-COVID drugs Pfizer lifted its 2026 revenue outlook by $500 million, driven by strong sales of non-COVID medicines. This signals that the core business is growing faster than expected, giving investors more confidence in future earnings.

    This is a new positive development that directly boosts investor confidence and is a key reason for the stock's movement.

  • Cost cuts expanded to $2.5 billion Pfizer widened its cost-cutting program to save an additional $2.5 billion. Lower expenses can protect profits even if sales slow, and the move shows management is taking action to improve financial health.

    This is a new operational improvement that supports profitability and is likely to be viewed positively by investors.

  • Pipeline advances: Lyme vaccine and obesity drug Pfizer moved forward its Lyme disease vaccine and obesity drug berobenatide, which could reach the market by 2028. These new products offer future revenue streams as older drugs face patent expirations.

    This is a new pipeline update that addresses long-term growth concerns and is a positive catalyst for the stock.

  • Patent lawsuits and pricing pressure persist Arbutus lawsuits over lipid nanoparticle technology add legal costs and uncertainty, while U.S. drug pricing pressure continues. Overall growth was just 1% with a net loss, and major drugs face patent expirations through 2030.

    These are ongoing risks that weigh on the stock and are important for a balanced view, even though some elements were previously known.

▲3▼1

Pfizer's pipeline advances, but pricing and patent worries persist

  • Obesity drug berobenatide targets 2028 approval Pfizer's lead obesity drug berobenatide is advancing in late-stage trials, with a potential 2028 approval. It aims to compete in a market expected to reach $114 billion by 2030. This offers a major new growth path as older drugs lose patent protection, supporting the stock.

    This is a new pipeline update that could drive future revenue growth, directly answering what's moving PFE.

  • Eliquis strength lifts partner Bristol Myers' outlook Bristol Myers raised its 2026 revenue guidance after Eliquis sales grew 19% in the first half. Pfizer co-markets Eliquis, so it shares in these profits. Stronger-than-expected sales mean more cash for Pfizer, helping offset declines elsewhere and supporting the stock.

    This new update shows a key Pfizer product performing well, directly boosting Pfizer's revenue outlook.

  • FDA approves updated COVID vaccine, EMA reviews Lyme shot The FDA approved Pfizer's XFG-adapted COVID vaccine for high-risk groups, allowing immediate U.S. distribution. Separately, the EMA validated Pfizer's Lyme disease vaccine application. These regulatory wins support near-term COVID sales and add a potential new vaccine revenue stream.

    These are new regulatory milestones that directly affect Pfizer's product sales and pipeline prospects.

  • Drug pricing pressure and patent cliff concerns linger The Trump administration is expected to announce a drug pricing agreement with mid-sized biotech firms, and Pfizer was among major companies urged to cut U.S. prices. Meanwhile, Pfizer's total growth was only 1% and it posted a net loss, with major drugs facing patent expirations through 2030.

    This highlights ongoing regulatory and competitive pressures that could weigh on Pfizer's future revenue and stock.

▲3▼1

Pfizer lifts guidance on non-COVID strength, adds cost savings and Lyme vaccine milestone

  • Pfizer raises 2026 revenue guidance on non-COVID drugs Pfizer beat Q2 estimates and raised its 2026 revenue forecast by $500 million to $60.5–$62.5 billion, driven by strong non-COVID products. This shows the core business is growing and helps offset declining COVID sales, supporting the stock.

    This is the main new positive event of the period and directly boosts investor confidence in Pfizer's growth.

  • Pfizer expands cost-cutting, expects $2.5 billion extra savings Pfizer announced an expansion of productivity initiatives expected to yield $2.5 billion in additional savings between 2027 and 2029, raising total net savings to about $9.7 billion. Lower costs improve future profits and cash flow, which supports the stock.

    This is a new financial development that improves Pfizer's profitability outlook and helps fund its dividend.

  • EMA validates Pfizer-Valneva Lyme disease vaccine application The European Medicines Agency validated the marketing application for Pfizer and Valneva's Lyme disease vaccine candidate, based on Phase 3 efficacy above 70%. If approved, it could be the first such vaccine in Europe, adding a new revenue stream and supporting the stock.

    This is a new regulatory milestone that advances a potential new vaccine product for Pfizer.

  • Arbutus patent lawsuits over lipid nanoparticle technology persist Arbutus filed three international patent infringement lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in COVID vaccines. This adds legal costs and uncertainty, weighing on the stock.

    This is a new legal development that creates ongoing risk and potential financial liability for Pfizer.

July 2026
▲3▼1

Pfizer gains on pricing deal, earnings beat, label wins

  • Voluntary drug-pricing deal cuts regulatory risk Pfizer struck a voluntary drug-pricing agreement with the Trump administration, easing the threat of forced price cuts. For investors, this lowers a major regulatory overhang and makes future revenue more predictable.

    This is a new, company-specific policy development that reduces a key risk for Pfizer.

  • Q2 earnings beat and raised 2026 guidance Pfizer reported second-quarter results above expectations and raised its full-year 2026 revenue outlook to $60.5–$62.5 billion. The beat and guidance hike signal stronger business momentum than previously thought.

    This is a fresh financial update that directly boosts investor confidence in Pfizer's near-term performance.

  • Label expansions and pipeline advances Pfizer won FDA label expansions for Ibrance and Padcev, got priority review for TALZENNA plus XTANDI, and advanced vitiligo and obesity programs. These broaden existing drugs' use and add future revenue sources.

    These are new regulatory and pipeline wins that expand Pfizer's commercial opportunities.

  • Patent lawsuits and patent-cliff worries persist International patent lawsuits over Comirnaty's lipid nanoparticles and upcoming 2027–2028 expirations for Ibrance and Eliquis keep weighing on Pfizer. These legal and patent risks threaten future sales and create uncertainty.

    This is a new legal development and a continuing overhang that pressures the stock.

▲3▼1

Pfizer's non-COVID drugs and pipeline progress offset COVID decline and patent cliff worries

  • Q2 earnings beat and raised revenue guidance Pfizer beat profit estimates and raised the low end of its 2026 revenue forecast to $60.5–$62.5 billion, driven by strong non-COVID drugs like Eliquis, Padcev, and Vyndaqel. This shows the core business is growing and helps offset declining COVID sales, supporting the stock.

    This is the period's biggest positive catalyst, directly boosting investor confidence in Pfizer's financial outlook.

  • Pipeline wins: LITFULO vitiligo and berobenatide obesity data Pfizer reported positive Phase 3 results for LITFULO in vitiligo and Phase 2b data showing its weight-loss drug berobenatide achieved 16% weight loss. These advance Pfizer's pipeline into new markets, offering future growth to replace aging drugs.

    These pipeline successes are new and show Pfizer's ability to develop new revenue sources, which is key to offsetting the patent cliff.

  • FDA priority review for TALZENNA+XTANDI and EU COVID vaccine authorization The FDA granted priority review to Pfizer's TALZENNA+XTANDI for earlier-stage prostate cancer, and the EU authorized Pfizer's updated COVID-19 vaccine. These regulatory milestones expand market opportunities and support sales in the near term.

    Regulatory progress is a new positive development that can lead to additional revenue streams and shows Pfizer's ability to navigate approvals.

  • Dividend strain and patent cliff concerns persist Pfizer's dividend payout exceeded 130% of earnings, raising concerns about financial strain as major drugs like Ibrance and Eliquis face patent expirations in 2027–2028. Management reaffirmed the dividend, but the high yield reflects investor worries about future cash flows.

    This is a key counterweight to the positive news, highlighting the financial challenges that could pressure the stock if not addressed.

▲3▼1

Pfizer's pipeline wins and pricing deals offset COVID decline and patent cliff

  • FDA approvals expand Ibrance and Padcev labels The FDA approved Ibrance for a new breast cancer type and Padcev with Keytruda for bladder cancer. These label expansions grow Pfizer's oncology sales and help replace falling COVID revenue, supporting the stock.

    New regulatory wins directly boost Pfizer's revenue outlook and investor confidence.

  • Competitor's ATTR-CM trial failure lifts Vyndamax AstraZeneca's ATTR-CM drug failed a late-stage trial, removing a potential rival to Pfizer's Vyndamax. This reduces competition for a $5.4 billion franchise, making Pfizer's rare-disease business more durable.

    Less competition protects a key Pfizer product's sales and pricing power.

  • Voluntary drug-pricing deal with Trump administration Pfizer signed a most-favored-nation pricing agreement, offering discounts on 30+ drugs. While it lowers some prices, it avoids harsher mandates and expands direct-to-consumer sales, providing clarity and reducing regulatory risk.

    The deal removes a major overhang and shows Pfizer adapting to new pricing rules.

  • Patent lawsuits over COVID vaccine technology Arbutus and Roivant filed international patent suits against Pfizer over lipid nanoparticles in Comirnaty, seeking injunctions and damages. This adds legal costs and uncertainty, weighing on the stock.

    New litigation creates financial risk and potential disruption to a major product.

Q2 2026
▼3▲1

Pfizer's mixed June: pipeline wins, leadership exit, policy setback

  • Obesity injection enters late-stage testing Pfizer moved its monthly obesity injection berobenatide into Phase 3 trials, aiming for approval in 2028 in a market that could be worth $120 billion. This gives the company a shot at a big new revenue source.

    This is a major pipeline advance that could drive future growth.

  • Lung cancer trial failure hits Seagen pipeline A Phase 3 trial of sigvotatug vedotin in lung cancer failed, raising doubts about the $43 billion Seagen acquisition. Pfizer shares fell 7.3% on the news, reflecting investor concern about the company's cancer drug prospects.

    This was a significant negative event that directly moved the stock price.

  • CFO departure creates uncertainty Pfizer's Chief Financial Officer is leaving in August, leaving a gap in financial leadership. For investors, a change at the top finance job can raise questions about strategy and execution.

    Leadership changes can affect investor confidence and future direction.

  • COVID drug emergency authorizations ended The termination of COVID-19 drug emergency use authorizations, associated with RFK Jr., reduces sales of Pfizer's Paxlovid. This policy shift cuts into a previously reliable revenue stream.

    This regulatory change directly impacts Pfizer's COVID product sales.

June 2026
▼3▲1

Pfizer's mixed June: pipeline wins, leadership exit, policy setback

  • Obesity injection enters late-stage testing Pfizer moved its monthly obesity injection berobenatide into Phase 3 trials, aiming for approval in 2028 in a market that could be worth $120 billion. This gives the company a shot at a big new revenue source.

    This is a major pipeline advance that could drive future growth.

  • Lung cancer trial failure hits Seagen pipeline A Phase 3 trial of sigvotatug vedotin in lung cancer failed, raising doubts about the $43 billion Seagen acquisition. Pfizer shares fell 7.3% on the news, reflecting investor concern about the company's cancer drug prospects.

    This was a significant negative event that directly moved the stock price.

  • CFO departure creates uncertainty Pfizer's Chief Financial Officer is leaving in August, leaving a gap in financial leadership. For investors, a change at the top finance job can raise questions about strategy and execution.

    Leadership changes can affect investor confidence and future direction.

  • COVID drug emergency authorizations ended The termination of COVID-19 drug emergency use authorizations, associated with RFK Jr., reduces sales of Pfizer's Paxlovid. This policy shift cuts into a previously reliable revenue stream.

    This regulatory change directly impacts Pfizer's COVID product sales.

▲3▼1

Pfizer's obesity pipeline and cheap valuation drive the story

  • Pfizer pushes into next-gen obesity drugs with monthly dosing Pfizer aims to lead in next-generation obesity therapies with monthly dosing, advancing 10 phase 3 studies and targeting 2028 approval. This is a huge potential market, and success could add a major new growth engine, pushing the stock up.

    This is a key new positive development that could drive future revenue growth.

  • Pfizer seen as deep value with potential to double in 3-5 years Pfizer is viewed as a deep value opportunity, trading at a low P/E with a 6.5% dividend yield. Bulls point to the Seagen acquisition, GLP-1 pipeline, and over 20 Phase 3 trials as catalysts that could double the stock over three to five years.

    This highlights the investment case and potential upside, attracting value investors.

  • RFK Jr. ends COVID-19 drug EUAs, hitting Paxlovid sales HHS Secretary RFK Jr. terminated Emergency Use Authorizations for COVID-19 drugs, including Pfizer's Paxlovid. This reduces future sales of the treatment, weighing on revenue and the stock price.

    This is a new regulatory setback that directly impacts a Pfizer product.

  • Pfizer's strong balance sheet fuels acquisition hopes CEO Albert Bourla says Pfizer has a very big balance sheet and can pursue transformative acquisitions. The company could deepen its weight loss portfolio by acquiring Kailera Therapeutics, signaling financial strength and deal capacity.

    This shows Pfizer's ability to grow through M&A, which could boost future earnings.

▲2▼2

Pfizer's mixed pipeline news: obesity bet advances, cancer drug fails, CFO exits

  • CFO departure adds uncertainty Pfizer's CFO Dave Denton will leave on August 15, raising questions about financial leadership and the 2026 outlook. Shares fell on the news. A new CFO search adds near-term uncertainty, which can weigh on the stock until a permanent replacement is named.

    This is a new event that directly affects investor confidence in Pfizer's financial strategy.

  • Lung cancer drug fails Phase 3 trial Pfizer's sigvotatug vedotin did not significantly improve overall survival in a Phase 3 lung cancer trial. The drug came from the $43 billion Seagen acquisition. This setback raises doubts about the Seagen pipeline and pushed the stock down 7.3% on June 25.

    This is a major clinical failure that impacts Pfizer's oncology growth story and investor sentiment.

  • Obesity pipeline advances with monthly injection Pfizer is moving berobenatide into Phase 3 trials, aiming for 2028 approval. It's a monthly GLP-1 shot for obesity, a market expected to reach $120 billion by 2035. Positive Phase 2b data and over 20 planned studies give Pfizer a shot at a lucrative new market.

    This is a new pipeline update that could drive future revenue growth and offsets negative news.

  • IBRANCE approved for expanded breast cancer use The FDA approved IBRANCE for a new type of metastatic breast cancer, making it the first CDK4/6 inhibitor for both HR+ and HER2+ patients. This expands the market for an existing drug and helps offset pipeline setbacks.

    This is a new regulatory approval that strengthens Pfizer's oncology franchise and provides a revenue boost.

Amgen Inc (AMGN)

Q3 2026
▲2▼2

Amgen Q3: Pelacarsen Blow Sinks Shares, Recalls and Rival Threats Weigh

  • Pelacarsen failure casts doubt on Amgen's olpasiran Novartis' heart drug pelacarsen failed, and because Amgen's similar olpasiran works the same way, investors feared it could fail too. Shares fell about 10% and BMO downgraded the stock.

    This was the single most severe event of the quarter, directly sinking the share price.

  • Court blocks Colorado's 70% Enbrel price cap A court blocked Colorado's 70% price cap on Enbrel, reducing regulatory risk for Amgen's biggest drug. This removes a threat that could have slashed revenue from a key product.

    A major legal win that eased a key overhang on the stock.

  • Q2 beat and raised guidance, key products grow 26% Amgen's Q2 earnings and revenue beat estimates, and the company raised its full-year guidance. Six key products grew 26%, showing the new drug lineup is driving growth.

    Strong financial results and raised outlook support the stock.

  • Recalls, competition, pipeline setback, cyberattack Corlanor and Sensipar recalls raised quality concerns. Merck's cheaper oral PCSK9 threatens Repatha, Sotyktu may erode Otezla, AMG 513 was discontinued, and a cyberattack triggered lawsuits.

    Multiple negative events that weighed on sentiment and future growth prospects.

September 2026
▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

  • Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.

    This is the main new force driving AMGN down this period.

  • BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.

    Analyst downgrade is a direct new negative catalyst for the stock.

  • IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.

    A major positive pipeline win that offsets some of the Lp(a) pessimism.

  • FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.

    Regulatory win that improves commercial practicality of a growth drug.

Latest
▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

  • Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.

    This is the main new force driving AMGN down this period.

  • BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.

    Analyst downgrade is a direct new negative catalyst for the stock.

  • IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.

    A major positive pipeline win that offsets some of the Lp(a) pessimism.

  • FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.

    Regulatory win that improves commercial practicality of a growth drug.

August 2026
▲2▼2

Amgen beats Q2, raises guidance, but obesity setback and cyberattack weigh

  • Q2 earnings beat and guidance raise Amgen reported Q2 adjusted EPS of $6.29 and revenue of $10.05B, beating estimates, and raised its 2026 guidance. Six key growth products grew 26%, reducing reliance on older drugs.

    This is a new positive fundamental development that directly supports the stock.

  • Repatha and Tezspire clinical wins Repatha cut death risk by 20% in a major heart trial, and Tezspire met all goals in an eosinophilic esophagitis study. These results lifted shares to a 52-week high and prompted analyst target hikes.

    New clinical data and analyst reactions are key drivers of the stock's move this period.

  • Obesity drug AMG 513 discontinued Amgen discontinued its obesity drug AMG 513, leaving MariTide trailing Eli Lilly and Novo Nordisk in the lucrative obesity market. This raises concerns about Amgen's competitive position.

    This is a new negative event that affects future growth prospects.

  • Cyberattack and drug-price pressure A July cyberattack exposed patient and proprietary data, triggering a class action investigation. Also, a looming US drug-price agreement with mid-sized biotechs could pressure Medicaid revenue.

    These are new risk factors that emerged during the period and could weigh on the stock.

▲3▼1

Amgen Hits 52-Week High on Q2 Beat, Repatha and Tezspire Wins

  • Repatha Cuts Death Risk 20% in Major Heart Trial Amgen's Repatha reduced death risk by 20% in high-risk heart patients in the VESALIUS-CV trial, a major win for its biggest growth drug. This strengthens the case for wider use and future sales, supporting a higher stock price.

    This is a new, high-impact clinical win that directly boosts confidence in Amgen's key growth driver.

  • Tezspire Meets All Goals in Eosinophilic Esophagitis Trial Amgen and AstraZeneca's Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, a chronic throat condition with few good treatments. This opens a new market and adds to Tezspire's growth story, lifting investor optimism.

    New positive trial results expand a key product's potential, a fresh catalyst for the stock.

  • US Drug Price Agreement with Mid-Sized Biotechs Looms The Trump administration is expected to announce a drug price agreement with mid-sized biotech firms, and Amgen was among companies urged to cut US prices. If Amgen is included, lower Medicaid prices could pressure revenue and weigh on the stock.

    This is a new regulatory risk that could directly affect Amgen's pricing and profits.

  • Analyst Fair Value and Price Targets Raised After Q2 Beat Following Amgen's strong Q2 results, analysts raised their fair value estimate to about $372 and several price targets into the $450 range, citing broad franchise strength. Higher targets can pull the stock up as investors adjust expectations.

    This is a new analyst reaction that reflects upgraded expectations and can influence the stock price.

▲2▼2

Amgen Q2 Beat and Guidance Raise Outweigh Data Breach and Obesity Setback

  • Q2 earnings beat and raised 2026 guidance Amgen reported Q2 adjusted EPS of $6.29, well above the $5.62 consensus, and revenue of $10.05 billion, up 10% and ahead of forecasts. Management raised full-year revenue and EPS guidance, signaling confidence in the business. This directly boosts the stock as investors see stronger profits ahead.

    This is the main new positive event that drove the stock up over 5% this period.

  • Key growth drivers show strong momentum Six key products, including Repatha, Evenity, Uplizna, and Imdelltra, grew 26% year-over-year and now make up nearly 70% of product sales. This reduces reliance on older drugs like Enbrel and Otezla, which are facing competition. The shift supports future revenue growth and lifts investor confidence.

    It explains the underlying strength behind the earnings beat and why the stock rose.

  • Cybersecurity breach and class action investigation Amgen disclosed a July cyberattack where sensitive patient and proprietary data was stolen. A law firm has launched a class action investigation. This creates legal and reputational risk, which could weigh on the stock, though Amgen says operations are not materially affected.

    It is a new negative event that could pressure the stock and is important for a balanced view.

  • Obesity drug AMG 513 discontinued; MariTide faces tough competition Amgen ended development of early-stage obesity drug AMG 513, leaving MariTide as its only obesity candidate. MariTide's weight-loss data trails Eli Lilly's and Novo Nordisk's drugs, and switching patients may be hard. This raises doubts about Amgen's ability to compete in the lucrative obesity market.

    It is a new setback that could limit future growth and is a key counterweight to the positive earnings.

July 2026
▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

  • Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.

    This is a major new legal win that directly supports Amgen's revenue outlook.

  • Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.

    New recalls create fresh regulatory and reputational risk that can hurt the stock.

  • New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.

    A new lower-priced competitor directly challenges a key Amgen growth drug.

  • Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.

    New competitive data shows a direct threat to an existing Amgen product.

▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

  • Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.

    This is a major new legal win that directly supports Amgen's revenue outlook.

  • Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.

    New recalls create fresh regulatory and reputational risk that can hurt the stock.

  • New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.

    A new lower-priced competitor directly challenges a key Amgen growth drug.

  • Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.

    New competitive data shows a direct threat to an existing Amgen product.

Q2 2026
▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

June 2026
▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

© 2026 MarketDXWhy